Therapeutic Effects of Ulinastatin on Experimental Crescentic Glomerulonephritis in Rats
| Autor: | Takuji Naruse, Tsugiyasu Kanda, Y Nojima, Akira Maezawa, Hideo Kanai, Ryuichi Koizumi |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
medicine.medical_specialty Neutrophils medicine.medical_treatment Kidney Glomerulus Intraperitoneal injection urologic and male genital diseases Rats Inbred WKY Nephrotoxicity chemistry.chemical_compound Glomerulonephritis Immune system Internal medicine Animals Humans Medicine Protease Inhibitors Glycoproteins Proteinuria biology urogenital system business.industry Macrophages Complement System Proteins medicine.disease Ulinastatin Rats Endocrinology chemistry Creatinine biology.protein Acute pancreatitis Rabbits Antibody medicine.symptom business Infiltration (medical) |
| Zdroj: | Nephron. 84:347-353 |
| ISSN: | 2235-3186 1660-8151 |
| Popis: | Ulinastatin is a potent protease inhibitor purified from the human urine that has been used clinically to treat acute pancreatitis and circulatory shock. In the current study, we evaluated the therapeutic effects of Ulinastatin in a rat model of crescentic glomerulonephritis (CrGN) and investigated its putative mechanisms. Wistar-Kyoto rats were injected with nephrotoxic serum and received daily intraperitoneal injection of Ulinastatin. Ulinastatin treatment significantly reduced proteinuria and glomerular crescentic formation. Moreover, glomerular infiltration of neutrophils and ED1+ cells (monocytes/macrophages) was significantly suppressed by Ulinastatin. In contrast, the glomerular deposition of heterologous (rabbit) and autologous (rat) antibodies was not changed. Neither serum complement activation nor the anti-rabbit immune response was affected by Ulinastatin administration. Our results suggest that Ulinastatin has preventive effects on rat experimental CrGN, mediated at least in part by inhibiting intraglomerular infiltration of inflammatory cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|